Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2024-2032
The global hospital acquired disease testing market size reached US$ 12.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 46.6 Billion by 2032, exhibiting a growth rate (CAGR) of 15.6% during 2024-2032.
Hospital-acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital-acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Other reasons can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patient's own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.
Market Trends:
Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital acquired disease testing market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on indication.
Breakup by Indication:
UTI (Urinary Tract Infection)
SSI (Surgical Site Infection)
Pneumonia
Bloodstream Infections
MRSA (Methicillin-Resistant Staphylococcus Aureus)
Others
Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.
Regional Insights:
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Competitive Landscape:
The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMйrieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.
Key Questions Answered in This Report
1. What is the market size for the global hospital acquired disease testing market 2023?
2. What is the global hospital acquired disease testing market growth 2024-2032?
3. What are the global hospital acquired disease testing market drivers?
4. What are the key industry trends in the global hospital acquired disease testing market?
5. What is the impact of COVID-19 on the global hospital acquired disease testing market?
6. What is the global hospital acquired disease testing market breakup by indication?
7. What are the major regions in the global hospital acquired disease testing market?
8. Who are the key companies/players in the global hospital acquired disease testing market?
Hospital-acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital-acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Other reasons can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patient's own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.
Market Trends:
Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital acquired disease testing market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on indication.
Breakup by Indication:
UTI (Urinary Tract Infection)
SSI (Surgical Site Infection)
Pneumonia
Bloodstream Infections
MRSA (Methicillin-Resistant Staphylococcus Aureus)
Others
Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.
Regional Insights:
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Competitive Landscape:
The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMйrieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.
Key Questions Answered in This Report
1. What is the market size for the global hospital acquired disease testing market 2023?
2. What is the global hospital acquired disease testing market growth 2024-2032?
3. What are the global hospital acquired disease testing market drivers?
4. What are the key industry trends in the global hospital acquired disease testing market?
5. What is the impact of COVID-19 on the global hospital acquired disease testing market?
6. What is the global hospital acquired disease testing market breakup by indication?
7. What are the major regions in the global hospital acquired disease testing market?
8. Who are the key companies/players in the global hospital acquired disease testing market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Indication
5.5 Market Breakup by Region
5.6 Market Forecast
5.7 SWOT Analysis
5.7.1 Overview
5.7.2 Strengths
5.7.3 Weaknesses
5.7.4 Opportunities
5.7.5 Threats
5.8 Value Chain Analysis
5.9 Porters Five Forces Analysis
5.9.1 Overview
5.9.2 Bargaining Power of Buyers
5.9.3 Bargaining Power of Suppliers
5.9.4 Degree of Competition
5.9.5 Threat of New Entrants
5.9.6 Threat of Substitutes
5.10 Price Analysis
6 MARKET BREAKUP BY INDICATION
6.1 UTI (Urinary Tract Infection)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 SSI (Surgical Site Infection)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Pneumonia
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Bloodstream Infections
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 MARKET BREAKUP BY REGION
7.1 North America
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Europe
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Asia Pacific
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Middle East and Africa
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Latin America
7.5.1 Market Trends
7.5.2 Market Forecast
8 COMPETITIVE LANDSCAPE
8.1 Market Structure
8.2 Key Players
8.3 Profiles of Key Players
8.3.1 Abbott Laboratories
8.3.2 Alere, Inc.
8.3.3 Becton, Dickinson and Company
8.3.4 bioMйrieux SA
8.3.5 F. Hoffmann-La Roche Ltd.
8.3.6 Hologic, Inc.
8.3.7 QIAGEN
8.3.8 Siemens Healthcare
8.3.9 Diatherix Laboratories, Inc.
8.3.10 Meridian Bioscience, Inc.
8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
8.3.12 Cepheid, Inc.
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 INTRODUCTION
4.1 Overview
4.2 Key Industry Trends
5 GLOBAL HOSPITAL ACQUIRED DISEASE TESTING MARKET
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Indication
5.5 Market Breakup by Region
5.6 Market Forecast
5.7 SWOT Analysis
5.7.1 Overview
5.7.2 Strengths
5.7.3 Weaknesses
5.7.4 Opportunities
5.7.5 Threats
5.8 Value Chain Analysis
5.9 Porters Five Forces Analysis
5.9.1 Overview
5.9.2 Bargaining Power of Buyers
5.9.3 Bargaining Power of Suppliers
5.9.4 Degree of Competition
5.9.5 Threat of New Entrants
5.9.6 Threat of Substitutes
5.10 Price Analysis
6 MARKET BREAKUP BY INDICATION
6.1 UTI (Urinary Tract Infection)
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 SSI (Surgical Site Infection)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Pneumonia
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Bloodstream Infections
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Others
6.6.1 Market Trends
6.6.2 Market Forecast
7 MARKET BREAKUP BY REGION
7.1 North America
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Europe
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Asia Pacific
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Middle East and Africa
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Latin America
7.5.1 Market Trends
7.5.2 Market Forecast
8 COMPETITIVE LANDSCAPE
8.1 Market Structure
8.2 Key Players
8.3 Profiles of Key Players
8.3.1 Abbott Laboratories
8.3.2 Alere, Inc.
8.3.3 Becton, Dickinson and Company
8.3.4 bioMйrieux SA
8.3.5 F. Hoffmann-La Roche Ltd.
8.3.6 Hologic, Inc.
8.3.7 QIAGEN
8.3.8 Siemens Healthcare
8.3.9 Diatherix Laboratories, Inc.
8.3.10 Meridian Bioscience, Inc.
8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
8.3.12 Cepheid, Inc.
LIST OF TABLES
Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2024-2032
Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
Table 5: Global: Hospital Acquired Disease Testing Market: Key Players
Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2024-2032
Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
Table 5: Global: Hospital Acquired Disease Testing Market: Key Players
LIST OF FIGURES
Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2023
Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2023
Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
Figure 7: Global: Hospital Acquired Disease Testing Industry: Value Chain Analysis
Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2023
Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2023
Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
Figure 7: Global: Hospital Acquired Disease Testing Industry: Value Chain Analysis
Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter’s Five Forces Analysis
Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
